Gilead Says U.S. Medicare Negotiated Price For HIV Drug Biktarvy Set At $2,600 Per 30-Day Supply From Jan. 1, 2028; Says Price Represents Approximately 38% Discount To Medicare List Price; Sees About $1.5 Billion Hit In 2028 From Lower Biktarvy Prices In Medicare

Loading news article.

Gilead Says U.S. Medicare Negotiated Price For HIV Drug Biktarvy Set At $2,600 Per 30-Day Supply From Jan. 1, 2028; Says Price Represents Approximately 38% Discount To Medicare List Price; Sees About $1.5 Billion Hit In 2028 From Lower Biktarvy Prices In Medicare | WAPE

Gilead Says U.S. Medicare Negotiated Price For HIV Drug Biktarvy Set At $2,600 Per 30-Day Supply From Jan. 1, 2028; Says Price Represents Approximately 38% Discount To Medicare List Price; Sees About $1.5 Billion Hit In 2028 From Lower Biktarvy Prices In Medicare

Article summary

Related companies

Comments —